Optimal Treatment of Metastatic TNBC

Presenter:

Hope S. Rugo MD
Professor of Medicine
University of California
San Francisco Comprehensive Cancer Center

TNBC comprises approximately 15% of newly diagnosed breast cancer cases and is defined by being estrogen-receptor negative, progesterone-receptor negative, and human epidermal growth factor receptor 2-negative. This breast cancer subtype is very aggressive, with a median overall survival slightly greater than 1 year. Furthermore, treatment options are limited. New and innovative therapies are being evaluated in patients to improve their outcomes, including progression-free survival and time to deterioration in health-related quality of life. Here, we present an expert-led review on current standards of care, as well as novel and emerging treatment regimens that are in the pipeline for approval by the United States Food and Drug Administration and/or under investigation.

Follow along with the slideset located here:
https://bit.ly/3krD3Gj